Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

Abstract

Purpose: There is a paucity of evidence on the impact of immune-mediated inflammatory disease (IMID) treatments on the immunogenicity of SARS-CoV-2 vaccination. The purpose of this literature review is to address the question of whether patients with IMIDs receiving secukinumab, a fully human anti–interleukin-17A monoclonal antibody, have an adequate immune response after SARS-CoV-2 vaccination. Materials and Methods: Clinical studies that evaluated the effect of secukinumab on immune responses in patients with IMIDs after SARS-CoV-2 vaccination were searched in publication databases, including Medline and Embase, until May 2022. Results: From the 53 articles identified, a total of 11 articles were included. Overall, the majority of the patients treated with secukinumab elicited an adequate immune response to SARS-CoV-2 vaccines. Patients receiving secukinumab for IMIDs developed cellular immune responses following vaccination with the BNT162b2 vaccine, and there were no significant differences in the overall humoral and cellular immune responses between patients and healthy individuals. The third dose of the BNT162b2 mRNA vaccine resulted in a positive antibody response in secukinumab-treated patients. Conclusion: The available data provide no evidence of impairment in immunological response to SARS-CoV-2 vaccines by secukinumab in patients with IMIDs.

Keywords:

• COVID-19
• immune-mediated inflammatory diseases
• SARS-CoV-2 vaccination
• secukinumab

Acknowledgements

The authors thank Avinash Thakur and Ramji Narayanan (Novartis Healthcare Pvt. Ltd, Hyderabad, India) for medical writing and editorial support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with Good Publication Practice guidelines (http://www.ismpp.org/gpp3).

Disclosure statement

P. Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, Eli Lilly, Novartis, Pierre Fabre, Sanofi and UCB. D. Simon received grants/contracts from Bayerisches Staatsministerium für Wissenschaft und Kunst, Doktor Robert Pfleger-Stiftung, Else Kröner-Fresenius Stiftung (EKFS), Innovative Medicines Initiative (European Union), AbbVie, Janssen-Cilag, Lilly, and Novartis. Consulting fees from Janssen-Cilag, Lilly. Support for attending meetings from Janssen-Cilag, Lilly. Advisory Board participation in AbbVie, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Novartis, UCB. I. Alarcon and E. Pournara are employees of Novartis Pharma AG, Basel, Switzerland. L. Puig has received grants/research support or participated in clinical trials (paid to institutions) from AbbVie, Almirall, Amgen, Boehringer Ingelheim, LEO-Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Consultation fees (paid to self) from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, LEO-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB. Honoraria for lectures, presentations, and speakers bureaus (paid to self) from Janssen, Lilly, Novartis, and UCB. Support for attending meetings and/or travel from Janssen and UCB.

Data availability statement

All data included in this review are available in the articles listed in references.

Additional information

Funding

This review was sponsored by Novartis Pharma AG, Basel, Switzerland.